GGrantIndex
← Leaderboards

Scott R Plotkin

Children'S Tumor Foundation

$5,244,687
Attributed
$7,794,890
Total exposure
7
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.2M · FY201325
$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$7,794,890 · 7

By mechanism

K12$5,585,690 · 1
R01$1,591,454 · 1
U24$574,838 · 1
R13$42,908 · 4

Top collaborators

Most similar at Children'S Tumor Foundation

Same institution · by research overlap

Others in their field

Top investigators on “Research Personnel

Research focus

Research PersonnelClinical TrialsFundingPublicationsDisciplineProgramsGrantAdultLeadershipOncologyNeurofibromatosis 2Clinical ResearchInterestTumorLaboratoriesPhysiciansGeneral HospitalsMassachusettsClinical SciencesMedical SpecialtiesMalignant NeoplasmsAwardBasic ScienceFeedback

Grant awards (17)

Training Program in Nervous System Tumors$803,367
K12 · FY2025 · CA · contact PI
Neurofibromatosis and Schwannomatosis Genes Variant Curation Expert Panel (VCEP)$284,144
U24 · FY2025 · NS · contact PI
Training Program in Nervous System Tumors$803,159
K12 · FY2024 · CA · contact PI
Neurofibromatosis and Schwannomatosis Genes Variant Curation Expert Panel (VCEP)$290,694
U24 · FY2024 · NS · contact PI
Training Program in Nervous System Tumors$760,906
K12 · FY2023 · CA · contact PI
Training Program in Nervous System Tumors$803,929
K12 · FY2022 · CA · contact PI
Training Program in Nervous System Tumors$803,929
K12 · FY2021 · CA · contact PI
Training Program in Nervous System Tumors$805,200
K12 · FY2020 · CA
Training Program in Nervous System Tumors$805,200
K12 · FY2019 · CA
Phase II trial of mTORC1/mTORC2 inhibitor AZD2014 for sporadic meningioma$389,008
R01 · FY2019 · CA
Designing clinical trials for cutaneous neurofibromas, an unmet medical need for patients with neurofibromatosis 1$9,898
R13 · FY2019 · CA · contact PI
Phase II trial of mTORC1/mTORC2 inhibitor AZD2014 for sporadic meningioma$401,040
R01 · FY2018 · CA
Phase II trial of mTORC1/mTORC2 inhibitor AZD2014 for sporadic meningioma$401,017
R01 · FY2017 · CA
Enhancing patient engagement in neurofibromatosis clinical trials$10,017
R13 · FY2017 · TR · contact PI
Phase II trial of mTORC1/mTORC2 inhibitor AZD2014 for sporadic meningioma$400,389
R01 · FY2016 · CA
Developing Endpoints to Facilitate Clinical Trials in Rare Diseases$9,993
R13 · FY2016 · CA · contact PI
2013 Neurofibromatosis (NF) Conference$13,000
R13 · FY2013 · NS · contact PI